23andMe weighing up sale of the company as cash runs dry
Once boasting a valuation of $6bn, 23andMe is now worth $100m and struggling to stay afloat.
Healthtech
Pfizer believes in the metaverse: will healthcare thaw the technology’s winter?
Amwell divests virtual psychiatric care business for $21m to boost cash flow
Innovation driving expansion in cardiovascular devices market
Healthtech collaborations are shaping diabetes management in Singapore, says analyst
Successful NaoTrac-assisted procedures mark first for Bolivian neurosurgery
SolasCure collaborates with USAISR for combat wound care
Digital health has evolved rapidly, but medical insurance hasn’t kept up
